WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced the PRECISION Registry, an ongoing study aimed at collecting data on the patterns of use, safety and effectiveness in the delivery and manipulation of percutaneous coronary intervention (PCI) devices. Dr. Giora Weisz, Associate Professor of Medicine at Columbia University Medical Center, will lead the study.
“Although manual PCI procedures are a widely accepted practice, I believe there is an opportunity for improvements to be made in stent size selection and precision movements that can only be offered with robotic assistance,” said Dr. Weisz. “We have seen initial clinical indications linked to the benefits of robotics during the CorPath PRECISE clinical trial, published recently, and with the launch of the PRECISION Registry, we expect to see continued trending towards improved clinical output resulting from the routine practice of robotics during PCIs.”
Corindus’ CorPath 200 System is the first and only FDA-cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. During a CorPath angioplasty procedure, the interventional cardiologist sits in the radiation shielded interventional cockpit. Using robotic precision, the interventional cardiologist advances stents and guidewires via a joystick with millimeter by millimeter precision. CorPath may improve clinical outcomes by enabling precise measurement of the anatomy, which could potentially lead to better stent placements.
“Corindus is committed to engaging clinical research and providing evidence-based claims related to the benefits of robotic angioplasty,” said David Handler, President and CEO of Corindus Vascular Robotics. “We’ve established the PRECISION Registry as a tool for gathering valuable data and insight on PCI procedures and the impact of robotic angioplasties on improved patient outcomes and increased physician safety.”
As a result of the increasing interest in the CorPath System, Corindus Vascular Robotics has grown its patent portfolio to now include more than 30 issued patents worldwide. Additionally, following FDA clearance in July 2012, Corindus has increased its workforce, including an expansion of its sales team, and has recently relocated its office to a larger facility in Waltham, Mass.
About Corindus Vascular Robotics
Corindus Vascular Robotics (http://www.corindus.com) is the global technology leader in robotic-assisted percutaneous coronary interventions (PCI). The Company’s FDA cleared CorPath® 200 System is the first medical device that offers interventional cardiologists PCI procedure control from an interventional cockpit. The CorPath open-platform technology and intellectual property will enable Corindus to address other segments of the vascular market, including peripheral, neuro and structural heart applications.